



## Inimex Appoints John North as President and Chief Executive Officer

FOR IMMEDIATE RELEASE

**Vancouver, B.C., Canada – June 8, 2005.**

Inimex Pharmaceuticals, Inc. is pleased to announce that it has appointed Dr. John R. North as President, Chief Executive Officer and Director.

Dr. North has more than twenty years of experience as a senior executive in the life sciences industry. He has been responsible for numerous successful applications to the FDA, including several therapeutic product INDs and NDAs, and has held senior operational positions with P&L responsibility.



Dr. North was Executive Vice President of R&D at Inimex for the past year. From 1998 until 2003, Dr. North served as Chief Scientific Officer at QLT, Inc. of Vancouver, BC. Prior to QLT, Dr. North had an extensive career in the industry, including appointments as Managing Director of Monotech Laboratories Ltd. and as Biotechnology Consultant at PA Technology Ltd., UK. Dr. North spent 12 years with various subsidiaries within the Beaufour Ipsen Group in the US and Europe, most recently as Head of Exploratory Development at Ipsen International in London and Paris.

Dr. North received a Ph.D. in Immunology and an M.A. in Natural Sciences from the University of Cambridge, England.

Inimex Chairman Bob Fildes noted that “John’s vast experience will accelerate product development at Inimex. He will directly assist in unlocking the broad product potential of their Technology Platform.”

### About Inimex Pharmaceuticals, Inc.

Inimex Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to the discovery, development, and commercialization of new medicines based on the selective modulation of the innate immune response. Major shareholders include the Business Development Bank of Canada, the Working Opportunity Fund (EVCC) Ltd., advised by Growthworks Capital, Inc., the Canadian Medical Discoveries Fund, Inc. and BC Medical Innovations Fund, Inc., advised by MDS Capital, Inc., BC Advantage Funds (EVCC) Ltd. and British Columbia Discovery Fund (VCC), Inc.,

For further information, please visit the company website, [www.inimexpharma.com](http://www.inimexpharma.com) or contact:

Roger Graham  
Vice President, Corporate Development  
Inimex Pharmaceuticals, Inc.  
Tel: 604-225-2251  
Fax: 604-225-2257  
[rgraham@inimexpharma.com](mailto:rgraham@inimexpharma.com)

*Certain statements in this announcement may contain forward-looking comments that involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking comments.*